Last reviewed · How we verify
NCT05160116
Influence of Timing of Switch Operation in Transposition of Great Arteries
trial in Transposition of Great Vessels in 151 participants. Completed in 10 June 2022.
30 April 2022
Quick facts
| Lead sponsor | Brugmann University Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 151 |
| Start date | 15 December 2021 |
| Primary completion | 30 April 2022 |
| Estimated completion | 10 June 2022 |
| Sites | 1 location across Belgium |
Conditions studied
- Transposition of Great Vessels — all drugs for Transposition of Great Vessels →
Sponsor
Brugmann University Hospital
Who can join
Under 1, any sex, with Transposition of Great Vessels. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Transposition of great vessels are usually corrected by an arterial switch operation. This operation is often done during the first week of life as surgical delays lead to deconditioned left ventricle. On the other hand early surgery carries also risks as neonatal physiology may have problems adapting to an intervention under cardiopulmonary bypass, possible pulmonary hypertension. Arterial switch operation between 2008 and 2020 done at our center will be reviewed. Primary outcome will be mortality or severe postoperative morbidity. Patients will be divided in 2 groups according to the presence or absence of the primary outcome. After propensity score matching, they will be analysed according to the timing of operation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05160116
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Transposition of Great Vessels
Currently open trials in the same condition.
- NCT05452720 — MASA Valve Early Feasibility Study · NA · recruiting
- NCT05809310 — Effects Branch PA Stenting d-TGA, ToF and TA · NA · recruiting
- NCT05524324 — Cardiac Resynchronization Therapy in Adult Congenital Heart Disease With Systemic Right Ventricle: RIGHT-CRT · NA · recruiting
- NCT04106479 — NIRS in Congenital Heart Defects - Correlation With Echocardiography · recruiting
- NCT04335448 — Comprehensive Long-term Follow up of Adults With Arterial Switch Operation · active not recruiting
Other Brugmann University Hospital trials
Trials by the same sponsor.
- NCT07267403 — Comparison of Modulations of Motor Brain Activity and SedLine After Median Nerve Stimulation in General Anesthesia · NA · recruiting
- NCT07267416 — Impact of Combined PSi + NIRS Monitoring in the Prevention of Postoperative Cognitive Disorders in Cardiac Surgery. · NA · recruiting
- NCT07413315 — Benefits of a Renal Rehabilitation Program Adapted to Uremic Patients on Daily Hemodialysis at Low Dialysate Flow Rate. · NA · recruiting
- NCT06292377 — Better Understanding of Fatigue After STroke · NA · recruiting
- NCT06160232 — Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05160116 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Brugmann University Hospital
- Last refreshed: 20 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05160116.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing